湖北济川药业股份有限公司2025 年半年度报告 公司代码：600566 公司简称：济川药业 湖北济川药业股份有限公司 2025 年半年度报告 1 / 157 湖北济川药业股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人曹龙祥、主管会计工作负责人严宏泉及会计机构负责人（会计主管人员）奚建 宏声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 ...

Group 1 - The traditional Chinese medicine sector saw a slight increase of 0.37% on August 21, with Renhe Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3771.1, up 0.13%, while the Shenzhen Component Index closed at 11919.76, down 0.06% [1] - Key stocks in the traditional Chinese medicine sector included Renhe Pharmaceutical, which rose by 10.03% to a closing price of 7.02, and Guizhou Bailing, which increased by 3.80% to 6.29 [1] Group 2 - On the same day, the traditional Chinese medicine sector experienced a net outflow of 596 million yuan from institutional investors, while retail investors saw a net inflow of 490 million yuan [2] - The stock performance of New Da Pharmaceutical declined by 6.14%, closing at 12.83, while Tianmu Pharmaceutical fell by 5.81% to 17.50 [2] - The overall trading volume and turnover for the sector indicated mixed investor sentiment, with significant outflows from major stocks [2] Group 3 - Major stocks like Jiuzhitang and Pianzai Guang experienced significant net inflows from institutional investors, with Jiuzhitang seeing a net inflow of 83.81 million yuan [3] - Conversely, Renhe Pharmaceutical had a net outflow of 38.75 million yuan from speculative investors, indicating a shift in trading dynamics [3] - The data reflects a complex interaction between institutional, speculative, and retail investors within the traditional Chinese medicine sector [3]

Core Viewpoint - As of August 20, a total of 119 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Jichuan Pharmaceutical, which has seen net buying for 15 consecutive trading days [1] - Other notable stocks with significant net buying days include Suzhou Bank, ST Guangwu, Te Bao Biological, Jinmoly Co., Ningbo Fuda, Dong'a Ejiao, Xidamen, and China Power [1]

Core Insights - As of August 19, a total of 138 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stock with the longest streak of net buying is Jichuan Pharmaceutical, which has seen net buying for 14 consecutive trading days [1] - Other notable stocks with significant net buying days include Dingyang Technology, Suzhou Bank, Zhongzhi Holdings, ST Guangwu, Zheshang Bank, Tebao Biological, Yangmei Chemical, and Dong'e Ejiao [1]

Core Insights - As of August 15, a total of 134 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stock with the longest streak of net buying is Qingsong Jianhua, which has seen net buying for 18 consecutive trading days [1] - Other notable stocks with significant net buying days include Jichuan Pharmaceutical (12 days), Dingyang Technology (11 days), Suzhou Bank, Zhongzhi Holdings, Hongchang Electronics, Everbright Jiabao, Yingte Group, and Jinko Technology, each with 10 or more days of net buying [1]

资金流向方面，今日主力资金净流出1391.60万元，占比成交额7.09%。其中，超大单净流出1023.81万 元、占成交额5.21%，大单净流出367.79万元、占成交额1.87%，中单净流出流入1091.05万元、占成交 额5.56%，小单净流入300.56万元、占成交额1.53%。 济川药业最新一期业绩显示，截至2025一季报，公司营业总收入15.25亿元、同比减少36.51%，归属净 利润4.40亿元，同比减少47.91%，扣非净利润3.92亿元，同比减少46.01%，流动比率4.934、速动比率 4.780、资产负债率17.27%。 天眼查商业履历信息显示，湖北济川药业股份有限公司，成立于1997年，位于荆州市，是一家以从事医 药制造业为主的企业。企业注册资本92241.816万人民币，实缴资本56359.5818万人民币。公司法定代表 人为曹龙祥。 通过天眼查大数据分析，湖北济川药业股份有限公司共对外投资了3家企业，参与招投标项目36次，专 利信息43条，此外企业还拥有行政许可1个。 来源：金融界 金融界消息 截至2025年8月15日收盘，济川药业（600566）报收于26.52元，下跌0.26%， ...

Group 1 - A total of 113 stocks in the Shanghai and Shenzhen markets have received net buying from main funds for 5 consecutive days or more as of August 14 [1] - The stock with the longest consecutive net buying days is Qingsong Jianhua, which has seen net buying for 17 trading days [1] - Other notable stocks with significant consecutive net buying days include Poly Development (12 days), Jichuan Pharmaceutical (11 days), Dingyang Technology (10 days), Zhongzhi Holdings (9 days), Huicheng Environmental Protection (9 days), Suzhou Bank (9 days), Nanwei Co. (8 days), and Everbright Jiabao (8 days) [1]

据iFind统计，截至8月13日，沪深两市共有109只个股连续5日或5日以上获主力资金净买入。连续获主 力资金净买入天数最多的股票是青松建化，已连续16个交易日获净买入；连续获主力资金净买入天数较 多的还有保利发展、博汇纸业、兴业银行、济川药业、山东药玻、伊利股份、鼎阳科技、普邦股份等 股，分别获11个、11个、10个、10个、10个、10个、9个、9个交易日净买入。 （文章来源：证券时报网） ...

（文章来源：证券时报网） 据iFind统计，截至8月8日，沪深两市共有160只个股连续5日或5日以上获融资净买入。连续获融资净买 入天数最多的股票是惠城环保，已连续20个交易日获净买入；连续获融资净买入天数较多的还有中国宝 安、济川药业、泰晶科技、赛伦生物、探路者、恒生电子、中国高科、新劲刚、利民股份、中集车辆等 股，分别获14个、13个、11个、11个、11个、11个、11个、10个、10个、10个交易日净买入。 ...

Core Insights - The report highlights the significant role of CFOs in listed companies, with the total salary scale for CFOs in A-share companies reaching 4.27 billion yuan in 2024 [1] - The average annual salary for CFOs in the A-share traditional Chinese medicine sector is 730,900 yuan [1] Salary Distribution - The top three highest-paid CFOs are Yan Hongquan from Jichuan Pharmaceutical with 1.78 million yuan, Li Chengguang from Yiling Pharmaceutical with 1.74 million yuan, and Ding Hongyan from Dong'e Ejiao with 1.71 million yuan [1] - The salary distribution shows that 44% of CFOs earn below 500,000 yuan, while 28% fall into the 500,000-1 million yuan range, and another 28% earn above 1 million yuan [1] Age and Education Distribution - CFOs aged 50-60 constitute 44% of the market, while those aged 40-50 account for 42%, and only 12% are under 40 [1] - In terms of educational background, 55% of CFOs hold a bachelor's degree, 33% have a master's degree, while only 2% have a technical secondary school education [1] Salary Changes - Zhang Shuyuan from Jilin Aodong experienced the largest salary decrease in 2024, with a year-on-year decline of 66.13% [1] - Sun Zhiqiang from Kunming Pharmaceutical saw the highest salary increase, with a year-on-year rise of 283.57% [1]